You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 376 - 387 of 387
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Recruiting
  • Hepatocellular Carcinoma
  • Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jul 23, 2021

Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma Trial in Sydney (Blood screening, Tissue screening)

Recruiting
  • Lung Cancer, Nonsmall Cell
  • +6 more
  • Blood screening
  • Tissue screening
  • Sydney, New South Wales, Australia
  • +1 more
Jan 19, 2022

Intrahepatic Cholangiocarcinoma Trial (Transcatheter arterial chemoembolization, Multi-target Drug Therapy, Immunocheckpoint

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Transcatheter arterial chemoembolization
  • +3 more
  • (no location specified)
Feb 17, 2022

TACE in Combination With ICIs for HCC: a Real-world Study

Recruiting
  • Hepatocellular Carcinoma
  • TACE+ICIs
  • TACE
  • Nanjing, China
    Gao-Jun Teng
Jul 22, 2021

Ovarian Cancer, Neoadjuvant Chemo, Anti-PD-1 Trial in Hangzhou (BGB-A317, albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5)

Recruiting
  • Ovarian Cancer
  • +3 more
  • BGB-A317
  • albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital of Zhejiang University School of Medi
Mar 23, 2021

Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease Trial in Beijing (PD-1 antibody, Chemoradiation, Albumin-Bound

Recruiting
  • Esophagus Cancer
  • +3 more
  • PD-1 antibody
  • +3 more
  • Beijing, Beijing, China
    Department of Radiation Oncology, National Cancer Center/Nationa
Mar 26, 2021

Nasopharyngeal Tumors Trial in Guangzhou (Tis-U-Sol)

Not yet recruiting
  • Nasopharyngeal Neoplasms
  • Guangzhou, Guangdong, China
    Affiliated Cancer Hospital & Institute of Guangzhou Medical Univ
Jun 3, 2021

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Oral Cancer, PD-1 Trial in Guangzhou (PD-1 with chemo, upright surgery)

Recruiting
  • Oral Cancer
  • PD-1
  • PD-1 with chemotherapy
  • upright surgery
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Nov 12, 2023

Esophageal Squamous Cell Carcinoma Trial in Chengdu (Tirelizumab, Paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Feb 8, 2022

Diffuse Large B-cell Lymphoma Trial in Hangzhou (CD19-7×19 CAR-T plus PD1 mAb)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • CD19-7×19 CAR-T plus PD1 monoclonal antibody
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 26, 2020

BCLC Stage C Hepatocellular Carcinoma Trial in Hangzhou (TACE, Tilelizumab, Sorafenib)

Not yet recruiting
  • BCLC Stage C Hepatocellular Carcinoma
  • TACE
  • +2 more
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Aug 10, 2021